Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1021-1030
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1021
Table 3 Response rate in each treatment regimen
| Capecitabine (n = 41) | S-1 (n = 40) | P value | |
| Complete response | 0 | 0 | |
| Partial response | 4 (9.8) | 1 (2.5) | |
| Stable disease | 5 (12.2) | 10 (25.0) | |
| Progressive disease | 32 (78.0) | 27 (67.5) | |
| Not available | 0 | 2 (5.0) | |
| Objective response rate, n (%) | 4 (9.8) | 1 (2.5) | 0.359 |
| Disease control rate, n (%) | 8 (19.5) | 11 (21.5) | 0.396 |
- Citation: Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030
- URL: https://www.wjgnet.com/1948-5204/full/v11/i11/1021.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i11.1021